Lupin Ltd is a leading pharmaceutical company from India and is amongst the top 10 generic companies in the world. It started its business in 1968 and over the years has become one of the largest pharmaceutical companies in India and the world. Its businesses include formulations, Active Pharmaceutical Ingredients (API), drug delivery systems and biotechnology. Its largest market is the North American region which contributed 38 per cent of its revenues in FY18, followed by India with 26 per cent and Asia-Pacific (APAC) with 17 per cent. In FY19, its total sales reached Rs 16,369.4 crore (US$ 2.34 billion) and in H1FY20 reached Rs 8,652.7 crore (US$ 1.24 billion).
Company Website: http://www.lupin.com
|2019|| Lupin launched Adhero, first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease |
Received approval for its propranolol Hydrochloride Extended-Release (ER) capsules from Health Canada.
Lupin’s subsidiary in South Africa declared commercial agreement with Creso Pharma
Nagpur facility wins ENR Global Best Project Award
Launched Doxercalciferol Injection, 4 mcg/2 ml multidose vials, for the treatments of secondary hyperparathyroidism in adult patients with CKD on dialysis.
|2017||Entered over the counter (OTC) market with launch of Softovac in India|
|2016||Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc.|
|2010||Became fifth largest generic player in the US|
|2004||Commenced US Brands Business with the launch of Suprax|
|2002||More than 100 patent filings|
|1993||Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs|
|1989||Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed|
|1980||Commissioned first Formulations plant and an R&D center at Aurangabad, Maharashtra|
Updated: May, 2019